Noninvasive prenatal testing identifies twice as many Down syndrome cases as second-trimester serum screening

A novel study has analyzed the cost-effectiveness of different Down syndrome (DS) screening strategies. The result confirms that noninvasive prenatal testing (NIPT) outperforms second-trimester serum screening (STSS) in accuracy and cost-effectiveness, as NIPT identifies twice as many DS cases as STSS.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup